The over-arching goal of our research is to understand the brain processes underlying the generation of symptoms and neurodegeneration in Parkinson disease (PD) and translate that understanding into the identification and development of novel therapeutics. Our research encompasses both potential symptomatic and disease-modifying therapies. We are working to develop therapies for
• the degenerative process that underlies loss of both dopaminergic and non-dopaminergic neurons in PD, and
• the symptoms of PD, including the motor and non-motor symptoms that are the direct result of the disease and those arising as complications to currently available treatments.
We are currently investigating new therapeutic targets and gene therapy-based approaches for PD. We are also conducting studies to develop new pre-clinical models of PD, and to optimize the delivery and safety of novel therapeutics.